Literature DB >> 18768391

Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells.

Andrew S McDaniel1, Jayme D Allen, Su-Jung Park, Zahara M Jaffer, Elizabeth G Michels, Sarah J Burgin, Shi Chen, Waylan K Bessler, Clemens Hofmann, David A Ingram, Jonathan Chernoff, D Wade Clapp.   

Abstract

Neurofibromatosis type 1 (NF1) is a common genetic disorder caused by mutations in the NF1 locus, which encodes neurofibromin, a negative regulator of Ras. Patients with NF1 develop numerous neurofibromas, which contain many inflammatory mast cells that contribute to tumor formation. Subsequent to c-Kit stimulation, signaling from Ras to Rac1/2 to the MAPK pathway appears to be responsible for multiple hyperactive mast cell phenotypes; however, the specific effectors that mediate these functions remain uncertain. p21-activated kinase 1 (Pak1) is a downstream mediator of Rac1/2 that has been implicated as a positive regulator of MAPK pathway members and is a modulator of cell growth and cytoskeletal dynamics. Using an intercross of Pak 1(-/-) mice with Nf1(+/-) mice, we determined that Pak1 regulates hyperactive Ras-dependent proliferation via a Pak1/Erk pathway, whereas a Pak1/p38 pathway is required for the increased migration in Nf1(+/-) mast cells. Furthermore, we confirmed that loss of Pak1 corrects the dermal accumulation of Nf1(+/-) mast cells in vivo to levels found in wild-type mice. Thus, Pak1 is a novel mast cell mediator that functions as a key node in the MAPK signaling network and potential therapeutic target in NF1 patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18768391      PMCID: PMC2597131          DOI: 10.1182/blood-2008-04-155085

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  The neurofibromatosis type 1 gene encodes a protein related to GAP.

Authors:  G F Xu; P O'Connell; D Viskochil; R Cawthon; M Robertson; M Culver; D Dunn; J Stevens; R Gesteland; R White
Journal:  Cell       Date:  1990-08-10       Impact factor: 41.582

2.  Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales.

Authors:  S M Huson; P S Harper; D A Compston
Journal:  Brain       Date:  1988-12       Impact factor: 13.501

3.  Mast cell and lymphoreticular infiltrates in neurofibromas. Comparison with nerve sheath tumors.

Authors:  M D Johnson; J Kamso-Pratt; C F Federspiel; W O Whetsell
Journal:  Arch Pathol Lab Med       Date:  1989-11       Impact factor: 5.534

4.  Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis.

Authors:  J E DeClue; A G Papageorge; J A Fletcher; S R Diehl; N Ratner; W C Vass; D R Lowy
Journal:  Cell       Date:  1992-04-17       Impact factor: 41.582

5.  Collagens in neurofibromas and neurofibroma cell cultures.

Authors:  J Peltonen; R Penttinen; H Larjava; H J Aho
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

6.  Mast cells in benign nerve sheath tumours.

Authors:  P Isaacson
Journal:  J Pathol       Date:  1976-08       Impact factor: 7.996

7.  Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells.

Authors:  Feng-Chun Yang; David A Ingram; Shi Chen; Cynthia M Hingtgen; Nancy Ratner; Kelly R Monk; Travis Clegg; Hilary White; Laura Mead; Mary Jo Wenning; David A Williams; Reuben Kapur; Simon J Atkinson; D Wade Clapp
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

8.  Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis.

Authors:  J R Starkey; P K Crowle; S Taubenberger
Journal:  Int J Cancer       Date:  1988-07-15       Impact factor: 7.396

9.  The rat c-kit ligand, stem cell factor, induces the development of connective tissue-type and mucosal mast cells in vivo. Analysis by anatomical distribution, histochemistry, and protease phenotype.

Authors:  M Tsai; L S Shih; G F Newlands; T Takeishi; K E Langley; K M Zsebo; H R Miller; E N Geissler; S J Galli
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

10.  Mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762NF.

Authors:  M K Dabbous; L Haney; G L Nicolson; D Eckley; D E Woolley
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

View more
  45 in total

Review 1.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

2.  Nf1-/- Schwann cell-conditioned medium modulates mast cell degranulation by c-Kit-mediated hyperactivation of phosphatidylinositol 3-kinase.

Authors:  Shi Chen; Sarah Burgin; Andrew McDaniel; Xiaohong Li; Jin Yuan; Mia Chen; Waleed Khalaf; D Wade Clapp; Feng-Chun Yang
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

3.  Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.

Authors:  Charles B Goodwin; Zhenyun Yang; Fuqin Yin; Menggang Yu; Rebecca J Chan
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

4.  Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.

Authors:  Anindya Chatterjee; Joydeep Ghosh; Baskar Ramdas; Raghuveer Singh Mali; Holly Martin; Michihiro Kobayashi; Sasidhar Vemula; Victor H Canela; Emily R Waskow; Valeria Visconte; Ramon V Tiu; Catherine C Smith; Neil Shah; Kevin D Bunting; H Scott Boswell; Yan Liu; Rebecca J Chan; Reuben Kapur
Journal:  Cell Rep       Date:  2014-11-13       Impact factor: 9.423

5.  Kinase suppressor of Ras (KSR1) modulates multiple kit-ligand-dependent mast cell functions.

Authors:  Mia Chen; Sarah Burgin; Karl Staser; Yongzheng He; Xiaohong Li; Mikella Robinson; Li Jiang; Rebecca J Chan; David Ingram; D Wade Clapp
Journal:  Exp Hematol       Date:  2011-07-01       Impact factor: 3.084

Review 6.  PAK signalling during the development and progression of cancer.

Authors:  Maria Radu; Galina Semenova; Rachelle Kosoff; Jonathan Chernoff
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

7.  Pak2 regulates hematopoietic progenitor cell proliferation, survival, and differentiation.

Authors:  Yi Zeng; Hal E Broxmeyer; Karl Staser; Brahmananda Reddy Chitteti; Su-Jung Park; Seongmin Hahn; Scott Cooper; Zejin Sun; Li Jiang; XianLin Yang; Jin Yuan; Rachelle Kosoff; George Sandusky; Edward F Srour; Jonathan Chernoff; D Wade Clapp
Journal:  Stem Cells       Date:  2015-05       Impact factor: 6.277

8.  A novel PAK1 variant causative of neurodevelopmental disorder with postnatal macrocephaly.

Authors:  Sachiko Ohori; Satomi Mitsuhashi; Revital Ben-Haim; Eli Heyman; Toru Sengoku; Kazuhiro Ogata; Naomichi Matsumoto
Journal:  J Hum Genet       Date:  2020-01-31       Impact factor: 3.172

9.  A Pak1-PP2A-ERM signaling axis mediates F-actin rearrangement and degranulation in mast cells.

Authors:  Karl Staser; Matthew A Shew; Elizabeth G Michels; Muithi M Mwanthi; Feng-Chun Yang; D Wade Clapp; Su-Jung Park
Journal:  Exp Hematol       Date:  2012-10-11       Impact factor: 3.084

10.  Down-regulated Six2 by knockdown of neurofibromin results in apoptosis of metanephric mesenchyme cells in vitro.

Authors:  Puhui Zhou; Tielin Chen; Yin Fang; Honglian Wang; Mi Li; Pengpeng Ma; Lu He; Qianyin Li; Tianming Liu; Xianggui Yang; Fang Nie; Xiaoyan Wang; Yue Yuan; Li Zhou; Rui Peng; Zhicheng Liu; Qin Zhou
Journal:  Mol Cell Biochem       Date:  2014-02-27       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.